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The incidence of protein conformational disorders is a problem affecting the aging 
population and is an increasing cost on the health system. These diseases involve the 
breakdown of control mechanisms within and outside of cells leading to accumulation 
of unfolded and misfolded proteins. The control of protein folding, both inside and 
outside the cell, is important to maintain the integrity of all proteins. Dysfunctions in this 
control may lead to the development of protein conformational disorders.  
 
Intracellularly the mechanisms monitoring the correct translation, modification, 
assembly and transport of synthesised proteins are very well studied. However, in the 
harsh extracellular environment, mechanisms to control protein folding need further 
investigation. Extracellular chaperones have recently been proposed as an important 
part of extracellular quality control for protein folding.  
 
The ubiquitous glycoprotein clusterin has been implicated in this extracellular quality 
control mechanism. A primary aim of the work described in this thesis was to examine 
the relationship between clusterin structure and function. This was done using three 
different approaches; characterisation of mutant clusterin expressed in transfected 
CHO cells; characterisation of enzymatically deglycosylated clusterin; and 
characterisation of bacterially expressed recombinant clusterin domains.  
 
Initially a panel of mutants was designed to disrupt predicted features of the protein, 
consisting of five point mutants and five truncation mutants. The clusterin molecules 
were expressed in CHO cells and were proteolytically processed with two subunits and 
appeared to be normally glycosylated. The mutant clusterin molecules appeared to be 




specific media proteins. In a rolling culture proteins in the media would be exposed to 
sheer stress and one of the actions of clusterin is to bind to exposed hydrophobicity on 
stressed proteins. A decrease in the amount of contaminating proteins copurified with 
clusterin when static cultures were used instead of rolling cultures supports this 
argument.  
 
In an effort to understand the importance of the glyscosylation of clusterin, the 
conjugated sugars were enzymatically removed to determine their effects on clusterin 
function. The success of the deglycosylation process was first verified using SDS-
PAGE and mass spectrometry. Structural features of the deglycosylated molecule 
were tested, with no change seen in the secondary structure of the deglycosylated 
protein compared to the native protein. A shift to slightly acidic pH produced no change 
in secondary structure as assessed by circular dichroism spectroscopy. Exposed 
hydrophobicity was seen to increase with the removal of the sugars but the Kd of the 
interaction with bisANS was not significantly different. At slightly acidic pH both the 
wild type and deglycosylated molecules exposed a greater amount of hydrophobicity to 
solution.  
 
Binding to the known clusterin ligand megalin was also tested with a similar binding 
affinity seen for both molecules, however the removal of sugars increased the rate at 
which the molecule bound to and dissociated from megalin. Binding of the 
deglycosylated molecule to known native ligands (IgG and GST) and stressed protein 
ligands (lysozyme and BSA) was not affected by the absence of sugar moieties. The 
chaperone activity of the deglycosylated molecule was also not different to the wild 
type molecule.  
 
Following the determination that the sugars appeared to have little effect on the activity 




domains (αN: D23-E112 and βC: R306-E449) were purified and their structure and 
function was examined. In the presence of a polar solvent both domains exhibited 
alpha helical secondary structure as expected based on amino acid analysis, though in 
aqueous buffer the domains had very little or no significant structure. The domains 
alone did not have any effect on the heat stressed precipitation of citrate synthase. 
Neither domain alone bound to heat-stressed lysozyme, however the αN domain 
bound to the native protein ligand IgG and this was enhanced at slightly acidic pH, as 
seen with native clusterin. The αN domain also bound with high affinity to LRP 
indicating that this domain of clusterin is likely to be involved in binding interactions of 
the entire molecule. Interaction between the αN and βC domains was also observed 
and further investigation is required to determine binding and chaperone activity of the 
interacting domains. 
 
Understanding the functional relationship between the structure and function of 
clusterin is important in understanding the role of clusterin in protein folding control. 
This knowledge may also be important in the development of novel treatments for the 
prevention or slowing of protein conformational diseases. The work in this manuscript 
showed that the deglycosylated form of clusterin is as potent a chaperone as the entire 
clusterin molecule. This indicated that a bacterially expressed form of clusterin may be 
used to further investigate the function of the molecule. Recombinant domains of 
clusterin were also studied to localise the regions of the molecule important in clusterin 
binding and chaperone function. Further investigation is needed, however the use of 
bacterially expressed recombinant proteins allows the potential development of 
recombinant chaperone-active clusterin which may ultimately be used as a therapeutic 
for protein conformational diseases. This research has gone some way to showing the 
best methods of characterising the structural relevance to the binding and chaperone 
activity of clusterin, and to providing a knowledge base for future investigations. 
